Clinical Trial Update: Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update investigating whether blood-based stromal activation biomarkers can guide tocilizumab therapy in esophageal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma

Drugs mentioned

• Tocilizumab (Actemra) (tocilizumab)

Snippet

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Conditions: Esophageal Adenocarcinoma, Oesophageal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING